{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:23:50Z","timestamp":1787833430705,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41582-026-01216-9","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:58:40Z","timestamp":1778155120000},"page":"533-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Newborn screening for spinal muscular atrophy: time is motor neuron"],"prefix":"10.1038","volume":"22","author":[{"given":"Didu S.","family":"Kariyawasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-0902","authenticated-orcid":false,"given":"Michelle A.","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"1216_CR1","unstructured":"Bishop, H. Jesy Nelson provides emotional update on twins\u2019 rare genetic condition. The Independent https:\/\/www.independent.co.uk\/bulletin\/culture\/jesy-nelson-twins-sma-update-b2911412.html (31 January 2026)."},{"key":"1216_CR2","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss, K. A. et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat. Med. 28, 1381\u20131389 (2022).","journal-title":"Nat. Med."},{"key":"1216_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","volume":"7","author":"DS Kariyawasam","year":"2023","unstructured":"Kariyawasam, D. S. et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc. Health 7, 159\u2013170 (2023).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1216_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns8030045","volume":"8","author":"STF Shih","year":"2022","unstructured":"Shih, S. T. F. et al. Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency. Int. J. Neonatal Screen. 8, 45 (2022).","journal-title":"Int. J. Neonatal Screen."},{"key":"1216_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam, D. S. T., Russell, J. S., Wiley, V., Alexander, I. E. & Farrar, M. A. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet. Med. 22, 557\u2013565 (2020).","journal-title":"Genet. Med."},{"key":"1216_CR6","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.eclinm.2021.100742","volume":"33","author":"DST Kariyawasam","year":"2021","unstructured":"Kariyawasam, D. S. T. et al. \u201cWe needed this\u201d: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. EClinicalMedicine 33, 100742 (2021).","journal-title":"EClinicalMedicine"},{"key":"1216_CR7","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/22143602241288095","volume":"11","author":"E Vr\u0161\u010daj","year":"2024","unstructured":"Vr\u0161\u010daj, E., Dangouloff, T., Osredkar, D. & Servais, L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J. Neuromuscul. Dis. 11, 1180\u20131189 (2024).","journal-title":"J. Neuromuscul. Dis."},{"key":"1216_CR8","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.lanepe.2025.101351","volume":"54","author":"N Olkhovych","year":"2025","unstructured":"Olkhovych, N. et al. Newborn screening for spinal muscular atrophy in Ukraine: from pilot project to national programme. Lancet Reg. Health Eur. 54, 101351 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1216_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/ijns7030033","volume":"7","author":"K Hale","year":"2021","unstructured":"Hale, K., Ojodu, J. & Singh, S. Landscape of spinal muscular atrophy newborn screening in the United States: 2018\u20132021. Int. J. Neonatal Screen. 7, 33 (2021).","journal-title":"Int. J. Neonatal Screen."},{"key":"1216_CR10","unstructured":"Department of Health and Social Care. England Rare Diseases Action Plan 2025. gov.uk https:\/\/www.gov.uk\/government\/publications\/england-rare-diseases-action-plan-2025 (2025)."},{"key":"1216_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(25)00048-0","volume":"405","author":"L Servais","year":"2025","unstructured":"Servais, L., Dangouloff, T., Muntoni, F., Scoto, M. & Baranello, G. Spinal muscular atrophy in the UK: the human toll of slow decisions. Lancet 405, 619\u2013620 (2025).","journal-title":"Lancet"},{"key":"1216_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15117","volume":"64","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva, A. M., Kariyawasam, D. S. T., Best, S., Wiley, V. & Farrar, M. A. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev. Med. Child Neurol. 64, 625\u2013632 (2022).","journal-title":"Dev. Med. Child Neurol."},{"key":"1216_CR13","unstructured":"World Health Organization. WHO Model List of Essential Medicines: Risdiplam. who.int https:\/\/www.who.int\/groups\/expert-committee-on-selection-and-use-of-essential-medicines\/essential-medicines-lists (5 September 2025)."},{"key":"1216_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213799","volume":"105","author":"MA Farrar","year":"2025","unstructured":"Farrar, M. A. et al. Gestational age at birth and clinical manifestations of spinal muscular atrophy. Neurology 105, e213799 (2025).","journal-title":"Neurology"},{"key":"1216_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.pathol.2025.02.004","volume":"57","author":"E Kirk","year":"2025","unstructured":"Kirk, E. et al. Guidelines for reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome and spinal muscular atrophy. Pathology 57, 539\u2013545 (2025).","journal-title":"Pathology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01216-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:03:12Z","timestamp":1787832192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1216"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01216-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"7 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S.K. has received honoraria for advisory board participation from Biogen, Roche and Novartis, and speaker\u2019s fees from Biogen, Novartis and Roche. M.A.F. is a site principal investigator for Roche and Novartis Gene Therapies Inc. clinical trials, and their institution has received funds for contract research related to the conduct of these trials. M.A.F. has received honoraria for advisory board participation from Biogen, Novartis and Roche, and has received speaker\u2019s fees from Biogen, Roche and Novartis. G.B. has participated in clinical trials sponsored by Roche, Novartis, Sarepta, Pfizer, NS Pharma, ReveraGen and Scholar Rock, and has received speaker and\/or consulting fees from Sarepta, PTC Therapeutics, Pfizer, Biogen, Novartis Gene Therapies Inc. (AveXis) and Roche, and grants from Sarepta, Roche and Novartis Gene Therapies Inc.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}